Association between the ERCC1 polymorphism and platinum-based chemotherapy effectiveness in ovarian cancer: a meta-analysis
Abstract Background Ovarian cancer is a prominent public health problem which affects people all around the world. Platinum-based chemotherapy is a common treatment for ovarian cancer, however, the effectiveness of chemotherapy varies from patient to patient. The excision repair cross complementatio...
Saved in:
Main Authors: | Ning Tang (Author), Dan Lyu (Author), Yan Zhang (Author), Haiping Liu (Author) |
---|---|
Format: | Book |
Published: |
BMC,
2017-06-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
<i>ERCC1</i> and <i>ERCC2</i> Polymorphisms Predict the Efficacy and Toxicity of Platinum-Based Chemotherapy in Small Cell Lung Cancer
by: Andrés Barba, et al.
Published: (2024) -
ERCC1 rs11615 polymorphism and chemosensitivity to platinum drugs in patients with ovarian cancer: a systematic review and meta-analysis
by: Yuqiang Zhang, et al.
Published: (2021) -
ERCC1 as a marker of prognosis and sensitivity to platinum-based chemotherapy in patients with stage III-IV non-small cell lung cancer
by: O. P. Kolesnik, et al.
Published: (2020) -
Gene polymorphism and prediction of toxicity to platinum‐based chemotherapy in patients with gynecologic cancer
by: Xuan Huang, et al.
Published: (2023) -
Predictive Value of Machine Learning for Platinum Chemotherapy Responses in Ovarian Cancer: Systematic Review and Meta-Analysis
by: Qingyi Wang, et al.
Published: (2024)